FTC Expands Reporting Requirements For Transfers Of Pharmaceutical Patent Rights

by Cadwalader, Wickersham & Taft LLP
Contact

The U.S. Federal Trade Commission (“FTC”) issued final changes to the premerger notification rules that affect whether pharmaceutical companies must report certain proposed acquisitions of exclusive patent rights to the FTC and the Antitrust Division of the Department of Justice (“DOJ”) for antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”).  The final rules apply solely to the pharmaceutical industry and will become effective 30 days after their publication in the Federal Register.  The amendments do not change the current HSR reporting requirements related to exclusive licenses in other industries.

Key Takeaways

  • A patent holder’s retention of limited manufacturing rights no longer renders a transaction non-reportable.
  • The FTC reaffirms that a patent holder’s retention of co-rights to assist in developing and commercializing the product does not render a transaction non-reportable.

*          *          *          *          *

“Exclusive” patent licensing in the pharmaceutical industry has become more complex over time, evolving from a straightforward license allowing a company to “make, use and sell” a drug under a patent to licensing arrangements where the patent holder may retain some manufacturing rights or co-rights for the purpose of joint development, marketing, or commercialization of the drug.  The rule largely clarifies and codifies the FTC’s current treatment of exclusive licenses, but reverses the FTC’s current practices with regard to licensing arrangements where the licensor retains limited rights.

The HSR Act requires parties to certain proposed transactions to file a notification with the FTC and DOJ and then observe a statutory waiting period before consummating the transaction.  The acquisition of a patent is treated as a potentially reportable acquisition of an asset under the HSR Act.  The transfer of patent rights, however, also may be deemed a potentially reportable asset acquisition. 

Under the FTC’s previous analysis, the transfer of exclusive rights to “make, use and sell” a product under a patent is a potentially reportable asset acquisition under the HSR Act.  The FTC’s longstanding practice also has been to treat the acquisition of exclusive marketing and distribution rights, but not manufacturing rights, as non-reportable.  Thus, up until now, pharmaceutical companies have not been required to report the transfer of exclusive rights to commercialize a product under a patent if the licensor retained the right to manufacture the product. 

The final rule defines and applies the concepts of “all commercially significant rights,” “limited manufacturing rights,” and “co-rights” in determining whether the rights transferred with regard to a patent or part of a patent in the pharmaceutical industry constitute a potentially reportable asset acquisition under the HSR Act. 

  • Commercially Significant Rights:  The final rule codifies the FTC’s current treatment of transactions within the pharmaceutical industry involving the transfer of “all commercially significant rights.”  These rights are defined as the exclusive rights to a patent that allow only the recipient of the exclusive patent rights to use the patent in a particular therapeutic area (or specific indication within a therapeutic area).  However, all commercially significant rights are deemed transferred even if the patent holder retains “limited manufacturing rights” or “co-rights.”
  • Limited Manufacturing Rights:  In certain licensing arrangements, the patent holder retains the right to manufacture while the licensee acquires the exclusive rights to use and sell under a patent (i.e., the licensor retains the right to manufacture exclusively for the licensee).  These transactions historically have been treated as non-reportable distribution agreements as opposed to potentially reportable asset acquisitions.  The final rule treats these types of exclusive arrangements as the potentially reportable transfer of “all commercially significant rights”—this is a significant departure from the FTC’s current practice.  
  • Co-Rights:  In some exclusive licensing arrangements, the licensor retains “co-rights,” often in order to facilitate co-development and co-marketing efforts.  The final rules codify the FTC’s current practice to treat the licensor’s retention of these co-rights as not rendering the license non-exclusive.  Thus, such licensing arrangements remain potentially reportable under the HSR Act.

Going forward

The final rules reflect the FTC’s view that, in the pharmaceutical industry, the right to commercialize often is more important than the right to manufacture.  If the patent holder is restricted to manufacture the product exclusively for the licensee, then the FTC will treat the arrangement the same as the patent holder giving the licensee the exclusive rights to make, use and sell the product covered by the patent.  Accordingly, the patent holder’s retention of limited manufacturing rights no longer will result in a non-reportable transaction.

The final rules also will codify the FTC’s informal position that the retention of co-rights to assist in developing and commercializing the product covered by the patent does not render a license non-exclusive, and thus the retention of such co-rights may still result in a reportable transaction.

The practical effect of these changes is that more transactions in the pharmaceutical industry will be reportable transactions.  The FTC has estimated an increase of approximately 30 transactions per year.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Cadwalader, Wickersham & Taft LLP | Attorney Advertising

Written by:

Cadwalader, Wickersham & Taft LLP
Contact
more
less

Cadwalader, Wickersham & Taft LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.